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Background: The 39-item Parkinson’s Disease Questionnaire (PDQ-39) is the most thoroughly validated and extensively
used self-report measure for the assessment of health-related quality of life in people with Parkinson’s (PwP). Given the
extent of its use and increasing emphasis on electronic data capture, an e-based version of the PDQ-39, the ePDQ, has
recently been developed. The aim of this short report is to present some key reliability and validity data that confirm
the psychometric quality of the ePDQ.
Findings: Participants were emailed a unique link to an online survey incorporating the ePDQ and demographic
questions. A total of 118 PwP fully completed the survey. Floor and ceiling effects were calculated to ensure responses
were not biased to extreme values. Consequently, score reliability was assessed by item-total correlations with a range
from 0.34 to 0.90. Cronbach’s alpha was calculated at between 0.64 and 0.95 for the eight domains of the ePDQ.
Construct validity was assessed by comparing domain scores in relation to disease duration and gender, with
hypothesised differences being largely confirmed. Construct validity was further assessed following a higher order factor
analysis which confirmed the appropriateness of calculating a summary index score. Subsequently, significant, but
moderate correlations were calculated between the ePDQ summary index score and disease duration and age at diagnosis.
Conclusions: Results indicate that the ePDQ largely mirrors the properties of its parent instrument, the PDQ-39, in terms of
reliability and validity. Potential users can therefore incorporate the ePDQ into computer-based data capture systems with
confidence.
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The 39-item Parkinson’s Disease Questionnaire (PDQ-
39) [1] is the most thoroughly validated and extensively
used self-report measure for the assessment of health-
related quality of life in people with Parkinson’s (PwP)
[2]. The measure has been shown to possess sound psy-
chometric properties [1,3-6] and its use is widely rec-
ommended [2,7,8]. Given the extent of its use and the
increasing emphasis on electronic data capture [9-12],
an electronic version of the PDQ-39, the ePDQ, has re-
cently been developed. The acceptability and usability
of the ePDQ have previously been reported, alongside a* Correspondence: david.morley@dph.ox.ac.uk
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unless otherwise stated.study assessing the impact of implementing non-response
options versus ‘forced response’ on response rates and
data completeness [13].
It has been suggested that full-scale psychometric ana-
lysis is not strictly necessary when developing electronic
patient reported outcomes (ePROs) which closely mirror
their paper-based equivalent [14]. However, given the ex-
tensive use of the PDQ-39, potential users of the electronic
version may require reassurance that its psychometric
properties are consistent with those of the paper-based
version. The aim, therefore, of this short report is to
present some key reliability and validity data that confirm
the psychometric quality of the ePDQ.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Ethical approval for the study was granted by the Medical
Sciences Inter Divisional Research Ethics Committee of the
University of Oxford (reference MSD-IDREC-C1-2013-17).
Participants
Recruitment of participants was undertaken with the sup-
port of Parkinson’s UK. Study details were distributed by
the charity’s Research Communications Office to their
research support network across the United Kingdom.
Potential participants were requested to contact the re-
search team by telephone or email.
Materials
The ePDQ [13], an electronically administered version of
the PDQ-39 [1] was administered using Qualtrics survey
software [15]. The measure totals 39 items, assessing eight
domains of health; Mobility, Activities of Daily Living,
Emotional Well-Being, Stigma, Social Support, Cognitions,
Communication and Bodily Discomfort. Domain scores
are coded on a scale of 0 (perfect health as assessed by the
measure) to 100 (worst health as assessed by the measure).
A summary index score can subsequently be calculated
from the eight domains outlined above [16]. Demographic
data (gender, age, marital status, ethnic origin and age at
or year of diagnosis) were obtained after participants had
completed the ePDQ items.
Procedure
After contacting the research team, participants were
emailed a unique link to the online survey which could be
completed in their own time and at a location of their
choice (e.g. home, workplace). A follow-up email was sent
after two weeks to non-responders.
Statistical analysis
Data was checked for normality of distribution and pres-
ence of outliers prior to statistical analysis. Floor and ceiling
effects were calculated for each domain of the ePDQ. Reli-
ability was assessed via corrected item-total correlations
and Cronbach’s alpha. Validity was determined through cal-
culation of differences between known groups using inde-
pendent samples t-tests. Higher order factor analysis was
used to create a summary index score. Relationships be-
tween the summary index score and relevant demographic
variables were tested via Pearson correlations coefficients
in order to further assess validity.
Results
A total of 118 PwP (66 males, 52 females) fully com-
pleted the ePDQ, a response rate of 91.4%. The mean
age was 63.48 years (standard deviation (SD) 8.66), mean
disease duration 5.73 years (SD 4.34) and mean age at
diagnosis 57.69 years (SD 9.00).Reliability
Floor and ceiling effects were calculated to ensure re-
sponses were not biased to extreme values (see Table 1).
Consequently score reliability was assessed by item-total
correlations (also reported in Table 1) with a range from
0.34 to 0.90. Cronbach’s alpha was calculated at between
0.64 and 0.95 for the eight domains of the ePDQ, indi-
cating sufficient to excellent internal reliability. Alpha
values for all domains can again be viewed in Table 1.
Validity
Construct validity was assessed by comparing domain
scores in relation to disease duration (groups split based
on median disease duration of 4 years) and gender, as seen
in Table 2. All domains anticipated as being significantly
different for disease duration were confirmed as such;
Mobility; Activities of Daily Living; Cognitive Impairment;
Communication; Bodily Discomfort. Hypothesised non-
significant differences between males and females were
confirmed in all but one of the eight ePDQ domains. Con-
struct validity was further assessed following a higher
order factor analysis which confirmed the appropriateness
of calculating a summary index score. One factor with an
Eigenvalue in excess of one was identified, accounting for
55.4% of variance (extraction method principal compo-
nent analysis). Each domain of the ePDQ loaded on this
one factor which had an eigenvalue of 4.4. Subsequently,
all eight domains of the ePDQ were summed to create the
summary index score. The mean value of the summary
index was 28.67 (S.D. = 16.66, min = 2.97, max = 91.93).
Finally, validity was further established by significant, but
moderate correlations between the ePDQ summary index
score and disease duration (r = .27, p < 0.01) and age at
diagnosis (r = −.27, p < 0.01).
Discussion
This short report has presented a brief analysis of the newly
developed ePDQ as a means of confirming that the meas-
ure reflects qualities that are consistent with the paper-
based PDQ-39 [1]. Floor and ceiling effects generally mirror
those of the parent instrument, largely falling within previ-
ously used criteria of 20% [17]. It is acknowledged, however,
that the domain of Social Support is almost double this fig-
ure, which may be a reflection of the inherent weakness of
three-item domains. Reliability of the ePDQ is confirmed
by two commonly used analyses, item-total correlations
and Cronbach’s alpha values. All item-total correlations are
in excess of previously defined criteria [18], the majority
significantly so, thereby confirming that item scores within
each domain are related to the overall domain score and
thus, to the underlying construct. Cronbach’s alpha coeffi-
cients are above the recommended level of 0.70 in all but
one domain, indicating good to excellent internal reliability
[19]. The one domain to fall below this figure, Cognitive
Table 1 ePDQ item-total correlations with domain floor






































































Emotional well-being 0.8 5.9 0.88
17 Felt depressed 0.71
18 Felt isolated and
lonely
0.80
19 Felt weepy or
tearful
0.72
Table 1 ePDQ item-total correlations with domain floor
and ceiling effects and Cronbach’s alpha values
(Continued)
20 Felt angry or bitter 0.67
21 Felt anxious 0.63
22 Felt worried about
the future
0.68
Stigma 0.8 22.0 0.83














Social support 0.8 39.8 0.76
27 Had problems with
close relationships
0.58












31 Had problems with
concentration
0.59







Communication 0.8 21.2 0.87
34 Had difficulty with
speech
0.78




36 Felt ignored by
people
0.67
Bodily discomfort 0.8 6.8 0.71
37 Had painful muscle
cramps or spasms
0.60
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Table 2 Comparison of ePDQ domains by disease duration and gender
Disease duration Gender
1-4 years 5-20 years p Male Female p
(n = 59) (n = 59) (n = 66) (n = 52)
Mobility 27.03 (26.87) 41.27 (25.47) <.00 31.86 (25.59) 37.07 (28.73) NS
Activities of daily living 28.11 (21.86) 39.62 (24.15) <.00 33.58 (23.01) 34.21 (24.67) NS
Emotional well-being 26.20 (21.16) 32.06 (20.10) NS 26.83 (20.87) 32.05 (20.45) NS
Stigma 17.58 (19.37) 24.68 (23.31) NS 19.51 (21.19) 23.20 (22.22) NS
Social support 14.12 (21.84) 15.34 (17.12) NS 17.30 (21.45) 11.70 (16.52) NS
Cognitive impairment 25.53 (18.29) 32.84 (17.96) <.05 29.45 (17.36) 28.85 (19.85) NS
Communication 22.88 (23.14) 33.05 (25.85) <.05 32.07 (23.03) 22.76 (26.51) <.05
Bodily discomfort 35.17 (23.67) 47.17 (24.05) <.00 38.13 (24.98) 45.03 (23.58) NS
(standard deviation; NS = non-significant).
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The validity of the ePDQ was confirmed via a number
of analyses. Firstly, a comparison of known groups was
made, (sometimes referred to as known groups validity).
Such an assessment is made where there are good rea-
sons to hypothesise that scores on a construct being
measured will differ between two groups [21], as has
been addressed in previous research [22,23]. When com-
paring domains by disease duration those hypothesised
as being significantly different were confirmed (Mobility,
Activities of Daily Living, Cognitive Impairment, Com-
munication and Bodily Discomfort). The three domains
of Emotional Well-Being, Stigma and Social Support are
deemed not to be as sensitive to disease duration with
results appearing to support this. Additionally, non-
significant differences between males and females were
observed in seven of the eight ePDQ domains. Construct
validity was further supported through the use of a
higher order factor analysis to confirm the appropriate-
ness of summing domain scores to create a summary
index score. This technique has been widely used in pre-
vious research [16,24-27]. Summary index scores were
found to correlate significantly, and in the anticipated
direction, with relevant demographic variables to pro-
vide further evidence of validity.
It is acknowledged that this study may be limited by the
relatively small sample size, although this is adequate for
the analyses reported. It is, however, recommended that
the ePDQ be further assessed in larger surveys and over
time in longitudinal studies. Assessment of the sensitivity
of the ePDQ is also required, although given that the reli-
ability and validity of the measure largely mirrors that of
the paper-based version, it is anticipated that sensitivity
data should follow a similar pattern. Additionally it is ac-
knowledged that the sample reported here may not be en-
tirely representative of the Parkinson’s population at large,as not all PwP will have access to electronically adminis-
tered measures or be computer literate.
In conclusion, data indicates that the ePDQ possesses
appropriate levels of reliability and validity and can be
incorporated into studies with confidence by those who
wish to do so. Should readers wish to make direct com-
parisons between the psychometric properties of the
PDQ-39 and ePDQ they can do so via the data pre-
sented here and the original validation paper for the
PDQ-39 [1] or current user manual [6]. Further details
of the ePDQ, the PDQ-39 and other related measures,
along with how to obtain copies, can be obtained from
DM or CJ.
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